利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

94 条记录 (耗时 0.045 秒)

    Landscaped antibodies and antibody fragments for clinical use
    21.
    发明授权
    Landscaped antibodies and antibody fragments for clinical use 失效
    景观抗体和抗体片段供临床使用

    公开(公告)号：US06953675B2

    公开(公告)日：2005-10-11

    申请号：US09185607

    申请日：1998-11-04

    申请人： Shui-on Leung ,  William J. McBride ,  Zhengxing Qu ,  Hans Hansen

    发明人： Shui-on Leung ,  William J. McBride ,  Zhengxing Qu ,  Hans Hansen

    IPC分类号： G01N33/53 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  C07K16/00 ,  C07K16/28 ,  C12N5/00 ,  C12N15/09 ,  C12P21/02 ,  C12P21/04 ,  C12P21/08 ,  G01N33/531 ,  G01N33/532

    CPC分类号： B82Y5/00 ,  A61K47/6803 ,  A61K47/6887 ,  A61K47/6893 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/28 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/54 ,  C07K2317/622 ,  C07K2319/00 ,  G01N33/532

    摘要： A method of making a glycosylated antibody or antibody fragment having a reactive ketone group on the glycosylated site is provided. The method comprises expressing a cell transfected with a vector encoding an antibody having one or more glycosylation sites in a culture medium comprising a ketone derivative of a saccharide or saccharide precursor and, in the case of an antibody fragment, fragmenting the resulting antibody into an antigen-binding antibody fragment. Methods of making immunoconjugates comprising the glycosylated antibodies or antibody fragments also are provided, wherein the antibody or antibody fragment is reacted with an agent comprising a ketone-reactive group. Glycosylated antibodies and antibody fragments having a reactive ketone group on the glycosylated site, immunoconjugates comprising such antibodies and antibody fragments and in vivo targeting methods using such antibodies, antibody fragments and immunoconjugates also are provided.

    摘要翻译： 提供了在糖基化位点制备具有反应性酮基团的糖基化抗体或抗体片段的方法。 该方法包括用包含糖或糖类前体的酮衍生物的培养基中编码具有一个或多个糖基化位点的抗体的载体转染的细胞，并且在抗体片段的情况下，将得到的抗体片段化为抗原 结合抗体片段。 提供了包含糖基化抗体或抗体片段的免疫缀合物的方法，其中所述抗体或抗体片段与包含酮反应性基团的试剂反应。 还提供糖基化抗体和在糖基化位点上具有反应性酮基的抗体片段，包含此类抗体的免疫缀合物和抗体片段以及使用此类抗体的体内靶向方法，抗体片段和免疫缀合物。

    RS7 antibodies
    23.
    发明授权
    RS7 antibodies 有权
    RS7抗体

    公开(公告)号：US07517964B2

    公开(公告)日：2009-04-14

    申请号：US11745896

    申请日：2007-05-08

    申请人： Serengulam Govindan ,  Zhengxing Qu ,  Hans Hansen ,  Davd M. Goldenberg

    发明人： Serengulam Govindan ,  Zhengxing Qu ,  Hans Hansen ,  Davd M. Goldenberg

    IPC分类号： C12P21/08 ,  C07K16/00 ,  A61K39/395 ,  C12P21/04 ,  G01N33/574

    CPC分类号： A61K45/06 ,  A61K39/39558 ,  A61K51/1045 ,  A61K51/1051 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3015 ,  C07K2317/21 ,  C07K2317/24

    摘要： This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.

    摘要翻译： 本发明涉及单价和多价单特异性结合蛋白和多价多特异性结合蛋白。 这些结合蛋白的一个实施方案具有一个或多个结合位点，其中每个结合位点与靶抗原或靶抗原上的表位结合。 这些结合蛋白的另一个实施方案具有两个或多个结合位点，其中每个结合位点对靶抗原上的不同表位具有亲和力，或对靶抗原或半抗原具有亲和力。 本发明还涉及可用于在宿主中表达这些功能性结合蛋白的重组载体。 更具体地，本发明涉及称为RS7的肿瘤相关抗原结合蛋白和其它EGP-1结合蛋白。 本发明还涉及人源化，人和嵌合RS7抗原结合蛋白，以及这种结合蛋白在诊断和治疗中的用途。

    RS7 antibodies
    24.
    发明授权
    RS7 antibodies 有权

    公开(公告)号：US08574575B2

    公开(公告)日：2013-11-05

    申请号：US13293608

    申请日：2011-11-10

    申请人： Serengulam V. Govindan ,  Zhengxing Qu ,  Hans J. Hansen ,  David M. Goldenberg

    发明人： Serengulam V. Govindan ,  Zhengxing Qu ,  Hans J. Hansen ,  David M. Goldenberg

    IPC分类号： A61K39/395

    CPC分类号： A61K45/06 ,  A61K39/39558 ,  A61K51/1045 ,  A61K51/1051 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3015 ,  C07K2317/21 ,  C07K2317/24

    摘要： This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.

    RS7 Antibodies
    25.
    发明申请
    RS7 Antibodies 有权
    RS7抗体

    公开(公告)号：US20120141372A1

    公开(公告)日：2012-06-07

    申请号：US13293608

    申请日：2011-11-10

    申请人： Serengulam V. Govindan ,  Zhengxing Qu ,  Hans J. Hansen ,  David M. Goldenberg

    发明人： Serengulam V. Govindan ,  Zhengxing Qu ,  Hans J. Hansen ,  David M. Goldenberg

    IPC分类号： A61K39/395 ,  A61P31/00 ,  A61P37/02 ,  A61K51/10 ,  A61P35/00

    CPC分类号： A61K45/06 ,  A61K39/39558 ,  A61K51/1045 ,  A61K51/1051 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3015 ,  C07K2317/21 ,  C07K2317/24

    摘要： This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.

    摘要翻译： 本发明涉及单价和多价单特异性结合蛋白和多价多特异性结合蛋白。 这些结合蛋白的一个实施方案具有一个或多个结合位点，其中每个结合位点与靶抗原或靶抗原上的表位结合。 这些结合蛋白的另一个实施方案具有两个或多个结合位点，其中每个结合位点对靶抗原上的不同表位具有亲和力，或对靶抗原或半抗原具有亲和力。 本发明还涉及可用于在宿主中表达这些功能性结合蛋白的重组载体。 更具体地，本发明涉及称为RS7的肿瘤相关抗原结合蛋白和其它EGP-1结合蛋白。 本发明还涉及人源化，人和嵌合RS7抗原结合蛋白，以及这种结合蛋白在诊断和治疗中的用途。

    Mammalian cell lines for increasing longevity and protein yield from a cell culture
    26.
    发明授权
    Mammalian cell lines for increasing longevity and protein yield from a cell culture 有权
    用于从细胞培养物增加寿命和蛋白质产量的哺乳动物细胞系

    公开(公告)号：US08153433B1

    公开(公告)日：2012-04-10

    申请号：US13287395

    申请日：2011-11-02

    申请人： David M. Goldenberg ,  Zhengxing Qu ,  Chien-Hsing Chang ,  Edmund A. Rossi ,  Jeng-Dar Yang ,  Diane Nordstrom

    发明人： David M. Goldenberg ,  Zhengxing Qu ,  Chien-Hsing Chang ,  Edmund A. Rossi ,  Jeng-Dar Yang ,  Diane Nordstrom

    IPC分类号： C12N5/10

    CPC分类号： C07K16/2896 ,  A61K2039/505 ,  C07K14/005 ,  C07K14/4747 ,  C07K16/00 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/3007 ,  C07K2317/24 ,  C07K2317/31 ,  C12N5/0694 ,  C12N15/85 ,  C12N15/86 ,  C12N2500/90 ,  C12N2501/48 ,  C12N2510/02 ,  C12N2710/20022 ,  C12N2740/10043 ,  C12P21/02

    摘要： Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hamiones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.

    摘要翻译： 公开了用于增加细胞培养物的寿命并允许增加蛋白质生产的组合物和方法，优选重组蛋白质，例如抗体，肽，酶，生长因子，白细胞介素，干扰素，hamiones和疫苗。 用凋亡抑制基因或载体如三重突变体Bcl-2基因转染的细胞可以在培养物中更长时间地存活，导致蛋白质生物合成的状态和产量的延长。 这样的转染细胞表现出最大的细胞密度，其等于或超过由亲本细胞系实现的最大密度。 转染的细胞也可以预先适应于无血清培养基中生长，大大减少了在无血清培养基中获得蛋白质产生所需的时间。 在某些方法中，预先调节的细胞可以在无血清条件下转化后用于蛋白质生产。 该方法优选涉及真核细胞，更优选哺乳动物细胞。